1	Adherence to a Mediterranean diet and leisure-time physical activity are protective								
2	factors against the initiation of antidepressant, anxiolytic, antipsychotic, and								
3	antiseizure drug use in older adults: a cohort study								
4									
5	Marta H. Hernandez <sup>1</sup> , Eleonora Fornara <sup>1</sup> , Camille Lassale <sup>2,3,4</sup> , Olga Castañer <sup>5,6</sup> , Ramón								
6	Estruch <sup>4,7,8</sup> , Emilio Ros <sup>4,7,9</sup> , Miguel Ángel Martínez-González <sup>4,10,11,12</sup> , Dolores Corella <sup>4,13</sup> , Nancy								
7	Babio <sup>4,14,15</sup> , José Lapetra <sup>4,16</sup> , Enrique Gómez-Gracia <sup>17</sup> , Fernando Arós <sup>4,18</sup> , Miquel Fiol <sup>4,19</sup> , Lluis								
8	Serra-Majem <sup>4,20,21</sup> , Antoni Riera-Mestre <sup>4,22,23,</sup> Alfredo Gea <sup>4,10,11</sup> , Carolina Ortega-Azorín <sup>4,13</sup> ,								
9	Andrés Díaz-López 4,14,15, Montserrat Fitó4,5, Álvaro Hernáez1,24,25,26								
10									
11	1. Blanquerna School of Health Sciences, Universitat Ramon Llull, Barcelona, Spain								
12	2. Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain								
13	3. Universitat Pompeu Fabra (UPF), Barcelona, Spain								
14	4. Consorcio CIBER, M.P. de Fisiopatología de la Obesidad y Nutrición (CIBEROBN),								
15	Instituto de Salud Carlos III, Madrid, Spain								
16	5. Cardiovascular Risk and Nutrition Research Group, Hospital del Mar Research Institute								
17	(IMIM), Barcelona, Spain								
18	6. Consorcio CIBER, M.P. de Fisiopatología de Epidemiología y Salud Pública								
19	(CIBERESP), Instituto de Salud Carlos III, Madrid, Spain								
20	7. August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.								
21	8. Internal Medicine Service, Hospital Clinic, Barcelona, Spain								
22	9. Lipid Clinic, Endocrinology and Nutrition Service, Hospital Clínic, Barcelona, Spain								
23	10. Department of Preventive Medicine and Public Health, Universidad de Navarra,								
24	Pamplona, Spain								
25	11. Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain								
26	12. Department of Nutrition, Harvard TH Chan School of Public Health, Boston, USA								
27	13. Department of Preventive Medicine, Universidad de Valencia, Valencia, Spain								
	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.								

28	14. Unitat de Nutrició Humana, Departament de Bioquimica i Biotecnologia, Universitat
29	Rovira i Virgili, Reus, Spain
30	15. Institut d'Investigació Sanitària Pere Virgili, Reus, Spain
31	16. Department of Family Medicine-Research Unit, Distrito Sanitario Atención Primaria
32	Sevilla, Sevilla, Spain
33	17. Department of Public Health and Psychiatry, Universidad de Málaga, Málaga, Spain
34	18. Department of Cardiology, Hospital Universitario de Álava, Vitoria, Spain
35	19. Health Research Institute of the Balearic Islands (IdISBa), Hospital Son Espases,
36	Palma de Mallorca, Spain
37	20. Instituto de Investigaciones Biomédicas y Sanitarias, Universidad de Las Palmas de
38	Gran Canaria, Las Palmas, Spain
39	21. Centro Hospitalario Universitario Insular Materno Infantil, Servicio Canario de Salud,
40	Las Palmas, Spain
41	22. Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge,
42	L'Hospitalet de Llobregat, Spain
43	23. Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain
44	24. REGICOR Study Group, Hospital del Mar Research Institute (IMIM), Barcelona, Spain
45	25. Consorcio CIBER, M.P. de Enfermedades Cardiovasculares (CIBERCV), Instituto de
46	Salud Carlos III, Madrid, Spain
47	26. Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway
48	
49	Corresponding author
50	Marta H. Hernández, PharmD, PhD
51	Blanquerna School of Health Sciences, Universitat Ramon Llull, Barcelona, Spain
52	Telephone: +34 93 253 32 56
53	e-mail: martahh1@blanquerna.url.edu
54	Address: Blanquerna School of Health Sciences, Carrer Padilla 326-332, 08025, Barcelona,
55	Spain

#### 56 ABSTRACT

57

58 **Background.** We aimed to investigate the association between long-term adherence to 59 MedDiet and LTPA levels and the initiation of antidepressant, anxiolytic, antipsychotic and 60 antiseizure medication in older adults.

61 Methods. We assessed the relationship between the cumulative average of MedDiet 62 adherence and LTPA and the initiation of medications in the PREvención con Dleta 63 MEDiterránea (PREDIMED) study. Sample sizes ranged from 5,940 for anxiolytics to 6,896 for 64 antipsychotics. Associations between the cumulative average of MedDiet adherence (per each 65 one-point increase in the adherence score) and LTPA (per each increase in 20 metabolic 66 equivalents of task-minute/day [METs-min/day]) with drug initiation were studied by 67 multivariable Cox regressions (covariates: age, sex, PREDIMED intervention group, recruitment site, education, smoking habit, BMI, alcohol, and energy intake; multiple 68 69 comparisons: Bonferroni method). We explored non-linear exposure-outcome associations 70 using smoothed cubic splines and the interaction among both exposures.

71 Results: One-point increases in MedDiet adherence score were associated with 23-28% less 72 initiation of antidepressants (hazard ratio [HR] 0.72, 95% confidence interval [CI] 0.67-0.77), 73 anxiolytics (HR 0.75, 95%CI 0.70-0.81), antipsychotics (HR 0.77, 95%CI 0.65-0.91), and 74 antiseizure drugs (HR 0.77, 95%CI 0.69-0.85). Associations for anxiolytics and antiseizure 75 drugs were particularly strong among participants with poor MedDiet adherence. Relationships 76 between LTPA and initiation of antidepressant and anxiolytic drug use were non-linear. Among 77 participants with the lowest LTPA values (0-150 METs-min/day), 20 METs-min/day increases 78 were associated with 20% less risk of initiating antidepressant use (HR 0.80, 95%CI 0.75-0.86) 79 and 15% less risk of initiating anxiolytic medication (HR 0.85, 95%CI 0.79-0.90). 20 METs-80 min/day increases were linearly associated with less initiation of antiseizure drugs (HR 0.96, 81 95%CI 0.94-0.99), and no clear associations were found for antipsychotic drugs. Individuals 82 with high MedDiet adherence (≥10 adherence points) and high LTPA levels (≥150 METs-83 min/day) showed 42-59% less risk of initiating psychoactive drugs (antidepressants: HR 0.41,

95%CI 0.30-0.56; anxiolytics: HR 0.54, 95%CI 0.41-0.71; antipsychotics: HR 0.45, 95%CI
0.21-0.95; antiseizure drugs: HR 0.58, 95%CI 0.37-0.90). The combination was additive for
antidepressants, antipsychotics and antiseizure drugs and synergistic for anxiolytics (*p*interaction = 0.076). **Conclusions:** Sustained adherence to MedDiet and LTPA were linked to lower initiation of
psychoactive drugs in older adults.

# 91 KEYWORDS

- 92 Mediterranean diet; leisure-time physical activity; antidepressants; anxiolytics; antipsychotics;
- 93 antiseizure drugs
- 94

# 95 ABBREVIATIONS

- 96 HR: hazard ratio
- 97 LTPA: leisure-time physical activity
- 98 MedDiet: Mediterranean Diet
- 99 METs-min/day: metabolic equivalents of task per minute per day
- 100 PREDIMED: PREvención con Dleta MEDiterránea

## 101 INTRODUCTION

102

103 Mental disorders represent a major burden for patients and society as they are leading causes 104 of disability [1] and are associated with increased mortality rates [2,3]. This burden of morbidity 105 and mortality is on the rise across all age, sex and socioeconomic levels [1,4]. The primary 106 pharmacological treatments for these conditions typically involve antidepressants, anxiolytics, 107 and, to a lesser extent, some antipsychotic and antiseizure medications. Older adults (≥65 108 years old) in European countries show a relevant prevalence of psychoactive drug use 109 according to the latest National Health Surveys [5,6]. However, despite significant 110 advancements, conventional treatments exhibit limited effectiveness and some adverse effects 111 [7–9]. Older adults face greater risks when exposed to these drugs due to characteristics in 112 this population such as changes in pharmacokinetics, polypharmacy, cognitive impairment, 113 and frailty [10]. Consequently, patients and clinicians are increasingly interested in exploring 114 complementary methods, such as adopting healthy dietary patterns or engaging in physical 115 activity, to reduce the burden of mental disorders in the elderly population or, at least, delay 116 and limit the initiation of psychoactive medication use [11,12].

117 Lifestyle psychiatry is a complex field due to the potential for reverse causation: an 118 unhealthy lifestyle may increase the incidence of mental disorders and neurological conditions, 119 which in turn are associated with a decline in dietary quality and reduced physical activity [13]. 120 However, recent meta-analyses of observational data have provided evidence of the 121 association between healthy diets and lower risk of depression [14] and of physical activity in warding off mental disorders [13]. Healthy dietary patterns such as the Mediterranean diet 122 123 (MedDiet) and leisure-time physical activity (LTPA) have shown a protective potential on 124 several risk factors for psychiatric and mental disorders such as oxidative stress, low-grade 125 inflammation, gut microbiome composition, blood pressure, and metabolic indicators [15-17] 126 [18–21].. Nevertheless, there is a scarcity of research investigating the association between 127 MedDiet and LTPA and the incidence of clinical outcomes related to mental disorders such as 128 the initiation of psychoactive medication use, using prospective study designs. Therefore, the

- main objective of this study is to investigate the association between long-term adherence to
  MedDiet and LTPA (individually and combined) and the initiation of psychoactive medication
- 131 in older adults at high cardiovascular risk.
- 132

#### 133 MATERIALS AND METHODS

134

#### 135 Study population

136 This study is an observational, prospective analysis utilizing data from participants enrolled in 137 the PREvención con Dleta MEDiterránea (PREDIMED) trial. The PREDIMED study was a 138 multicenter, randomized controlled trial conducted in Spain from 2003 to 2010. Its principal 139 objective was to assess the effects of a nutritional intervention based on a MedDiet 140 supplemented with extra-virgin olive oil and mixed nuts, compared to a low-fat control diet, on 141 the primary prevention of significant cardiovascular events in older adults at high 142 cardiovascular risk. [22]. Eligible individuals were women (aged 60-80 years) and men (aged 143 55-80 years) without cardiovascular disease at enrolment but with type 2 diabetes or at least 144 three of the following risk factors: hypertension (systolic blood pressure  $\geq$ 140 mmHg, diastolic 145 blood pressure  $\geq$ 90 mmHq, use of antihypertensive drugs), high concentrations of low-density 146 lipoprotein cholesterol (>160 mg/dL), low levels of high-density lipoprotein cholesterol <50 147 mg/dL in women, (<40 mg/dL in men), body mass index >25 kg/m<sup>2</sup>, smoking, and family history 148 of premature coronary disease (<55 years old in first degree male relatives, <65 years old in 149 first degree female relatives).

For the present investigation, we used the PREDIMED data as an observational prospective cohort. We therefore adjusted all analyses for intervention groups. Of the 7,447 participants, we first excluded participants with no baseline data on MedDiet adherence (n =22), no data from food frequency questionnaire (necessary for the estimated alcohol and energy intake, n = 39), outliers of the MedDiet adherence longitudinal average (n = 14), outliers of the LTPA longitudinal average (n = 39), and no medication use data (n = 328). Analyses of initiation of psychoactive drugs were performed in non-users at study baseline. Therefore, we

- 157 also excluded users of each specific drug at baseline in the respective analyses. The study
- 158 flow chart with the definitive sample sizes for all analyses is available in **Figure 1**. Our study is
- 159 presented following the STrengthening the Reporting of Observational Studies in Epidemiology
- 160 guidelines for reporting cohort studies.
- 161
- 162 Figure 1. Flow chart.
- 163



164

165 Exposures: adherence to a Mediterranean diet and leisure-time physical activity

166 At each visit, adherence to a MedDiet was assessed using the MedDiet adherence score. This

167 score was based on a screener designed to evaluate the adherence to 14 dietary traits of the

168 MedDiet, validated for Spanish adults [23]. The consumption of the following items contributed

169 positively: (1) use of olive oil as main fat for cooking/seasoning; (2)  $\geq$ 4 tablespoons/day of olive 170 oil; (3)  $\geq$ 3 servings/week of mixed nuts (30 g); (4)  $\geq$ 2 servings/day of vegetables; (5)  $\geq$ 3 171 servings/day of fruit; (6)  $\geq$ 3 servings/week of legumes (150 g, boiled); (7)  $\geq$ 3 servings/week of 172 fish or seafood; (8) ≥2 servings/week of "sofrito"-based dishes (recipes with a base of stir-fried 173 onion, garlic, tomato/pepper, and herbs cooked in olive oil); (9) wine in moderation (100 mL/day 174 on average, within meals); (10) <1 serving/day of red and processed meat; (11) preference of 175 poultry and rabbit over red and processed meat; (12) <1 serving/day of butter, margarine, or 176 cream; (13) <1 carbonated or sugar-sweetened beverage/day; and (14) <2 servings/week of 177 non-homemade pastries or sweets [23].

The estimation of LTPA was conducted using the Minnesota Leisure-Time Physical Activity Questionnaire, validated in both Spanish men and women [24,25]. This questionnaire captured information on the frequency and duration of sixty-seven activities performed by participants over the course of the previous year. LTPA was quantified in metabolic equivalents of task-minute per day (METs-min/d) by multiplying the metabolic equivalents of task associated with each activity by its average duration in minutes per day.

184

#### 185 Outcomes: initiation of use of psychoactive drugs

186 During the baseline and yearly follow-up examinations, information was gathered on 187 medication use. Using the list of all the drugs that were considered in each family of 188 psychoactive drugs available in Spain in 2003-2010 with their respecting Anatomical 189 Therapeutic Chemical codes available in the Supplemental Material, we created variables of 190 use (yes/no) of antidepressants, anxiolytics, antipsychotics, and antiseizure drugs. We defined 191 the incidence of the initiation of use of any antidepressant, anxiolytic, antipsychotic, and 192 antiseizure drug among those who were non-users at baseline. Initiation of use referred to the 193 commencement of medication use that persisted for a minimum of three subsequent follow-up 194 visits and drug use was unreported in only one visit between these three [26].

195

196

### 197 Other variables

198 Trained professionals gathered initial data on various factors, including age (continuous), sex, 199 educational (primary/secondary/higher/unavailable), attainment the prevalence of 200 cardiovascular risk factors at baseline (diabetes, hypercholesterolemia, hypertriglyceridemia, 201 and hypertension; yes/no), baseline body mass index (continuous), and baseline smoking 202 status (never/former/current smoker) [22,27]. Using a validated 137-item semiguantitative food 203 frequency questionnaire, we determined the alcohol consumption (in grams/day) and energy 204 intake (in kilocalories/day) at baseline [27].

205

# 206 Statistical analyses

The characteristics of the participants are described using means and standard deviations for normally distributed continuous variables, medians and interquartile ranges for non-normally distributed continuous variables, and proportions for categorical variables, overall and across groups defined by MedDiet adherence (low [<10 points] and high [≥10 points]) and by LTPA levels (an arbitrary threshold for low [<100 METs-min/day] and high levels [≥100 METsmin/day]).

213 We examined the relationships between the cumulative mean of MedDiet adherence 214 or LTPA levels and the risk of initiating psychoactive medication use (as hazard ratios, HR) 215 using Cox proportional hazards regression models. The cumulative mean of MedDiet adherence or LTPA was calculated as the average of all MedDiet adherence scores or LTPA 216 217 values up until the occurrence of the outcome (incident cases) or the last available study visit 218 (non-cases). Participants with outlier values in the cumulative mean of MedDiet adherence 219 score (<5 points) or LTPA levels (>1000 METs-min/day) were excluded from the analysis. The 220 reference cut-point was set at the minimum value for each exposure variable (5 points for 221 MedDiet adherence score and 0 METs-min/day for LTPA). The follow-up time for each event 222 was the time elapsed between the date of entry into the study and the date of the event or end 223 of follow-up (December 1, 2010), whichever came first. As these are non-acute events, we 224 assume that the occurrence of the event is dated at the midpoint between the last visit at which

225 the volunteer was not treated with the medication and the first visit at which the treatment was 226 registered[26,28,29]. The models were adjusted for sex, recruitment site, educational level (as 227 strata variables), age, smoking habit, body mass index, alcohol consumption, energy intake, 228 and intervention group. MedDiet adherence analyses were further adjusted for LTPA at 229 baseline, while the LTPA analyses were further adjusted for MedDiet adherence score at 230 baseline. To address intra-cluster correlations, robust variance estimators were used in all 231 survival analyses considering as clusters the members of the same household [22]. Results 232 were reported as HRs per each 1-point increase in MedDiet score and per each increase in 20 233 METs-min/day for LTPA (equivalent to increasing 40 minutes/week of brisk walking or Pilates, 234 or 30 minutes/week of dancing or aerobic classes). We corrected our findings in linear analyses 235 for multiple comparisons (two exposures  $\times$  four outcomes = eight comparisons) by the 236 Bonferroni method (*p*-value threshold < 0.00625).

237 We also examined the potential non-linear relationships between the cumulative mean 238 of MedDiet adherence or LTPA levels and the risk of initiating psychoactive medication use. 239 Initially, we explored whether a model using smoothed cubic splines (with K+4 degrees of 240 freedom) to model the relationship between the exposure and the outcome. We used a 241 likelihood ratio test to assess if this fitted the data better than a simple linear term. When the 242 test was significant, we used smoothed cubic splines graphically present the associations [30]. 243 We also reported the association between MedDiet adherence or LTPA and the risk of drug 244 initiation at the lowest part of the curves (after graphic inspection, for participants with MedDiet 245 adherence scores ranging from 5 to 8 points and LTPA levels ranging from 0 to 150 METs-246 min/day).

Additionally, we investigated whether the combination of high MedDiet adherence ( $\geq 10$ points [31]) and high LTPA levels ( $\geq 150$  MET-min/day, based on our findings, see below) was associated with a lower risk of drug use initiation, either additively or synergistically. Participants were classified into four groups: 1) low MedDiet adherence + low LTPA levels (reference group); 2) low MedDiet adherence + high LTPA levels; 3) high MedDiet adherence + low LTPA levels; and 4) high MedDiet adherence + high LTPA levels. We examined the

difference in the risk of drug use initiation for groups 2, 3, and 4 compared to the reference
group using Cox proportional hazards regression models. To assess potential synergy, we
applied a likelihood ratio test comparing models with and without the interaction term for
"MedDiet adherence × LTPA levels." A significant interaction would suggest that the
combination of the two exposures is associated with a stronger relationship than expected from
their independent associations.
We performed the analyses using the "survival" package in R Software (version 4.3.1).

260 Code for data management and analysis is available in

261 <u>https://github.com/alvarohernaez/MedDiet\_LTPA\_psychoactive\_drugs</u>.

### 262 RESULTS

263

# 264 Study population

- 265 The participants had an average age of 67 years, 58% of them were women, 14% we current
- smokers and –as per the selection criteria– they had a high prevalence of cardiovascular risk
- factors at baseline: 83% hypertension, 72% hypercholesterolemia, 49% diabetes, 47% obesity,
- 268 29% with hypertriglyceridemia (**Table 1**). Participants with a high adherence to a MedDiet and
- 269 high LTPA levels were more likely to be men, to have higher education, lower prevalence of
- 270 cardiovascular risk factors (such as diabetes, hypertriglyceridemia, hypertension, and obesity),
- and slightly higher intakes of energy and alcohol.
- The analytical samples were as follows: for antidepressants, n = 6,215, with a median follow-up of 4.2 years and 7.9% became new users; for anxiolytics, n = 5,940, with a 4.2-year follow-up and 8.8% became new users; for antipsychotics, n = 6,896, with a 4.7-year follow-up and 1.1% became new users; for antiseizure medications, n = 6,878, with a 4.7-year follow-up and 2.8% became new users.

# 277 **Table 1.** Population description

	All	MedDiet adherence score			LTPA levels			
	participants	(cumulative average)			(cumulative average)			
		Low	High	<i>p</i> -value	Low	High	<i>p</i> -value	
Age, years	67.0	67.2	66.7	0.001	67.6	66.8	<0.001	
(mean ± SD)	± 6.17	± 6.25	± 6.07)		± 6.50)	± 6.05)		
Females	4,080	2,277	1,803	<0.001	1,277	2,803	<0.001	
( <i>n</i> , %)	(57.8%)	(60.9%)	(54.2%)		(75.3%)	(52.2%)		
Education:				0.001			<0.001	
Primary	5,367	2,895	2,472		1,344	4,023		
( <i>n</i> , %)	(76.0%)	(77.5%)	(74.3%)		(79.2%)	(75.0%)		
Secondary	1,066	539	527		240	826		
( <i>n</i> , %)	(15.1%)	(14.4%)	(15.8%)		(14.1%)	(15.4%)		
Higher	503	230	273		82	421		
( <i>n</i> , %)	(7.12%)	(6.16%)	(8.21%)		(4.83%)	(7.85%)		
Not available	127	72	55		31	96		
( <i>n</i> , %)	(1.80%)	(1.93%)	(1.65%)		(1.83%)	(1.79%)		
Tobacco use:				0.001			<0.001	
Never smokers	4,345	2,356	1,989		1,194	3,151		
( <i>n</i> , %)	(61.5%)	(63.1%)	(59.8%)		(70.4%)	(58.7%)		
Ex-smokers	1,733	848	885		293	1,440		
( <i>n</i> , %)	(24.5%)	(22.7%)	(26.6%)		(17.3%)	(26.8%)		
Current smokers	985	532	453		210	775		
( <i>n</i> , %)	(13.9%)	(14.2%)	(13.6%)		(12.4%)	(14.4%)		
Type-II diabetes	3,442	1,925	1,517		862	2,580		
( <i>n</i> , %)	(48.7%)	(51.5%)	(45.6%)	<0.001	(50.8%)	(48.1%)	0.055	
Hypercholesterolemia	5,087	2,667	2,420	0.216	1,210	3,877	0.467	

( <i>n</i> , %)	(72.0%)	(71.4%)	(72.7%)		(71.3%)	(72.3%)	
Hypertriglyceridemia	2,045	1,181	864		556	1,489	
( <i>n</i> , %)	(29.0%)	(31.6%)	(26.0%)	<0.001	(32.8%)	(27.7%)	<0.001
Hypertension	5,834	3,136	2,698		1,451	4,383	
( <i>n</i> , %)	(82.6%)	(83.9%)	(81.1%)	0.002	(85.5%)	(81.7%)	<0.001
BMI categories:				<0.001			<0.001
<25.0 kg/m <sup>2</sup>	523	237	286		90	433	
( <i>n</i> , %)	(7.40%)	(6.34%)	(8.60%)		(5.30%)	(8.07%)	
25.0-29.9 kg/m <sup>2</sup>	3,207	1,564	1,643		583	2,624	
( <i>n</i> , %)	(45.4%)	(41.9%)	(49.4%)		(34.4%)	(48.9%)	
≥30.0 kg/m²	3,333	1,935	1,398		1,024	2,309	
( <i>n</i> , %)	(47.2%)	(51.8%)	(42.0%)		(60.3%)	(43.0%)	
Alcohol, g/d	1.49	1.09	4.38	<0.001	0.68	2.17	<0.001
(median, 1 <sup>st</sup> -3 <sup>rd</sup>	[0.00;10.4]	[0.00;8.84]	[0.00;12.4]		[0.00;5.92]	[0.00;11.7]	
quartile)							
Energy, kcal/d	2,274	2,201	2,356	<0.001	2,239	2,285	0.009
(mean ± SD)	± 604	± 609	± 587		± 633	± 594	

278

#### 279 MedDiet adherence and risk of psychoactive drug initiation

280 A one-point increase in cumulative MedDiet adherence was linearly associated with a 28% 281 less risk of initiating antidepressant use (HR 0.72, 95% CI 0.67 to 0.78, Figure 2A), a 25% 282 reduced risk of initiating anxiolytic medication (HR 0.75, 95% CI 0.70 to 0.81, Figure 2B), a 283 23% less risk of initiating antipsychotic use (HR 0.77, 95% 0.65 to 0.91, Figure 2C), and a 284 23% reduced risk of initiating antiseizure drugs (HR 0.77, 95% 0.69 to 0.85, Figure 2D). The 285 risk of initiating anxiolytics, antipsychotics, and antiseizure drugs was better explained by a 286 non-linear equation. There was a greater reduction in the risk of starting anxiolytics or 287 antiseizure for each one-point MedDiet score increase in participants with low adherence

scores (5-8 points) —a 55% lower risk for anxiolytics (Figure 2B) and a 43% lower risk for
antiseizure drugs (Figure 2D). In the case of antipsychotics (Figure 2C), the association
between greater MedDiet adherence and a lower risk of initiating such treatment was only
observed among participants with greater adherence (8 points or more).

292



293

**Figure 2.** Hazards ratios and confidence intervals of the association between long-term adherence to a MedDiet and the risk of initiating the use of antidepressants (A), anxiolytics (B), antipsychotics (C) and antiseizure medication (D). Cox proportional hazards regression models with smoothed cubic splines were stratified by sex, recruitment site, and educational level, and adjusted for: age, smoking habit, body mass index, alcohol consumption, energy

intake, leisure-time physical activity, and PREDIMED intervention group. Robust variance
estimators were used to account for intra-cluster correlations.

301

# 302 LTPA levels and risk of psychoactive drug initiation

303 A 20 METs-min/day increases in LTPA were linearly associated with a 3% reduced risk of 304 initiating antidepressant use (HR 0.97, 95% CI 0.95 to 0.98, Figure 3A) and a 4% less risk of 305 initiating antiseizure drugs (HR 0.96, 95% CI 0.94 to 0.99, Figure 3D), and nominally linked to 306 a 2% reduced risk of initiating anxiolytic use (HR 0.98, 95% CI 0.97 to 1.00, Figure 3B). 307 However, the risk of initiating antidepressant and anxiolytic drug use was better explained by 308 non-linear equations. Among participants with the lowest LTPA values (0-150 METs-min/day), 309 20 METs-min/day increments in LTPA were associated with a 20% reduced risk of initiating 310 antidepressant use (Figure 3A) and a 15% less risk of initiating anxiolytic medication (Figure 311 **3B**). No clear associations were found for antipsychotic drugs (**Figure 3C**).





314 Figure 3. Association between long-term levels of leisure-time physical activity and the risk of 315 initiating the use of antidepressants (A), anxiolytics (B), antipsychotics (C) and antiseizure 316 drugs (D). Cox proportional hazards regression models with smoothed cubic splines were stratified by sex, recruitment site, and educational level, and adjusted for: age, smoking habit, 317 318 body mass index, alcohol consumption, energy intake, adherence to a MedDiet, and 319 PREDIMED intervention group. Robust variance estimators were used to account for intra-320 cluster correlations.

322 Combination of MedDiet adherence and LTPA levels and risk of initiation of psychoactive drug

323 use

324 High levels of MedDiet adherence (≥10 score points) and LTPA (≥150 METs-min/day) 325 combined were associated with lower initiation of psychoactive therapy: 59% less risk of 326 initiating antidepressant use (HR 0.41, 95% CI 0.30 to 0.56), 46% less risk of initiating 327 anxiolytics (HR 0.54, 95% CI 0.41 to 0.71), 55% less risk of initiating antipsychotics (HR 0.45, 328 95% CI 0.21 to 0.95) and 41% less risk of initiating antiseizure therapy (HR 0.58, 95% CI 0.37 329 to 0.90) (Figure 4). The magnitude of the association of high MedDiet and high LTPA combined was synergistic for anxiolytics (p-value for interaction = 0.076) and additive for 330 331 antidepressants, antipsychotics, and antiseizure medications.







334 psychoactive drugs.

#### 335 DISCUSION

336

337 Among older adults at high cardiovascular risk, we found that adherence to a MedDiet was 338 associated with a lower risk of initiating the use of antidepressants, anxiolytics, antipsychotics, 339 and antiseizure drugs. In the case of anxiolytics and antiseizure drugs, the association was 340 particularly strong among participants with poor sustained adherence to a MedDiet. Our 341 findings also indicate a strong association between slight increases in LTPA (equivalent to 40 342 minutes/week of brisk walking or Pilates, or 30 minutes/week of dancing or aerobic classes) 343 and lower risk of initiating the use of antidepressants, anxiolytics and antiseizure medication. 344 The magnitudes of the associations were stronger at lower levels of LTPA. Furthermore, 345 individuals with high levels of both exposures show a particularly strong association with lower 346 risk of initiation of psychoactive drugs, which was synergistic for anxiolytic medication.

347 Previous studies have highlighted the neuroprotective properties of a traditional 348 MedDiet on mental health. These benefits could be due to its capacity to reduce oxidative 349 stress and low-grade inflammation thanks to its array of bioactive compounds, including 350 antioxidants, polyunsaturated and monounsaturated fatty acids, and prebiotic fiber [18.32.33]. 351 Our results show an association between higher adherence to a MedDiet and a lower incidence 352 of initiating antidepressant, anxiolytic, antipsychotic, and antiseizure medications in older 353 adults, with a particularly pronounced association for anxiolytics and antiseizure drugs among 354 those with very low MedDiet adherence sustained in time. High adherence to a MedDiet has 355 already been linked to lower incident depression [14]. However, to the best of our knowledge, 356 our study is the first to reveal that the MedDiet is linked to a reduced incidence of clinical 357 outcomes related to anxiety, psychosis, and epilepsy. Prior research in this area includes only 358 two cross-sectional studies that inversely correlated the MedDiet with anxiety symptoms in 359 elderly individuals [34,35] and one cross-sectional study that examined the relationship between diet quality and schizophrenia [36], and no studies that have investigated the 360 361 relationship of MedDiet with any clinical manifestation of epilepsy in adults.

362 Our results have also shown a link between increases in LTPA and a reduced incidence 363 of initiating antidepressant and anxiolytic medications among participants with very low LTPA 364 levels, as well as a relationship with lower initiation of antiseizure medication. Our findings are 365 consistent with previous evidence, as exercise interventions have been shown to effectively 366 treat symptoms of depression [37], anxiety [38], and epilepsy [39]. Our results also suggested 367 a trend towards a lower incidence of initiating antipsychotic medication. Although this trend 368 was not entirely significant, likely due to the low incidence rate in our population (1.1%), it 369 aligns with previous evidence indicating that physical activity is beneficial for improving 370 symptoms of psychotic disorders [40]. However, it should be noted that our results extend 371 beyond previous evidence by showing that modest increases in physical activity-equivalent 372 to a weekly session of 30-50 minutes of mild to moderate intensity exercise—are linked to a 373 lower risk of starting antidepressant or anxiolytic medication, especially in those significantly 374 below the recommended LTPA levels.

375 Our findings also suggest a synergistic association between a high adherence to 376 MedDiet diet combined with high levels of LTPA and the initiation of anxiolytic drugs, as well 377 as an additive relationship with the initiation of antidepressants, antipsychotics, and 378 antiepileptic drugs. A healthy diet combined with physical activity has been traditionally linked 379 to decreased mortality and lower incidence of chronic cardiometabolic disease [41,42], and 380 their combination has been associated with reduced initiation of use of cardiovascular drugs 381 in older adults [26]. Additionally, this combination has been linked to enhanced mental 382 wellbeing [43], particularly in terms of depression [44] and improved symptoms of psychosis 383 [45]. However, to the best of our knowledge, this is the first study to report similar findings in 384 relation to mental health medications and a potentially synergistic benefit regarding anxiety.

We acknowledge some limitations in our study. Firstly, our analyses were based on data from the PREDIMED trial, which primarily focused on dietary intervention and did not include specific advice on LTPA. As a result, we treated the data as a cohort study, adjusting all our analyses for the intervention group. Nevertheless, the use of cumulative averages of MedDiet adherence and LTPA levels as exposure variables, instead of a single baseline

390 measurement, is a strength of the study. Secondly, due to the available data, we could only 391 collect categorical information regarding drug use, preventing us from studying dose changes 392 or other aspects of medication use. Thirdly, the initiation of psychoactive-related therapy was 393 not a predetermined endpoint in the PREDIMED study. Therefore, there was no 394 standardization of treatment and patients were managed according to the clinical practice of 395 the attending physicians and participating hospitals. Fourthly, main exposures and certain 396 covariates, such as alcohol and energy intake, relied on self-reported data, which introduces 397 the possibility of misclassification and potential bias. Lastly, our conclusions are applicable 398 specifically to older adults at high cardiovascular risk and may not be generalizable to other 399 populations.

#### 400 CONCLUSIONS

401

402 In a cohort of older adults at high cardiovascular risk, our results showed that both higher 403 adherence to a MedDiet and LTPA levels were associated with a lower incidence of initiating 404 common psychoactive medication, individually and combined. These findings underscore the 405 potential of a healthy diet and regular physical activity to improve mental health and 406 neurological outcomes among older individuals. Our work sets the stage for future randomized 407 controlled trials to assess the effectiveness of MedDiet and physical activity interventions in 408 preventing the onset of depression, anxiety, psychotic disorders, and seizures, particularly 409 given the prevalence and disabling nature of these conditions in older adults, along with their 410 associated economic burden on health systems.

# 411 ETHICS APPROVAL AND CONSENT TO PARTICIPATE

412 The study protocol of the PREDIMED study complied with the Declaration of Helsinki for 413 Medical Research involving Human Subjects. It received approval from institutional ethic 414 committees at all recruitment sites. The protocol of this sub-study received approval from the 415 Hospital del Mar Ethics Committee (Barcelona, Spain). The PREDIMED study protocol was 416 registered with the International Standard Randomized Controlled Trial Number 417 ISRCTN35739639 (http://www.isrctn.com/ISRCTN35739639) and is available in the 418 PREDIMED study website (http://www.predimed.es). All participants provided written informed 419 consent before joining the study.

420

# 421 CONSENT FOR PUBLICATION

422 Not applicable.

423

#### 424 AVAILABILITY OF DATA AND MATERIALS

425 The dataset analyzed during the current study cannot be made publicly available due to 426 national data regulations and ethical considerations, including the absence of explicit written 427 consent from study participants to make their deidentified data available upon study 428 completion. However, data described in the manuscript will be provided to bona fide 429 investigators for collaboration upon request and approval. Requests can be made by sending 430 а letter to the PREDIMED Steering Committee (predimed-steering-

- 431 <u>committee@googlegroups.com</u>).
- 432

#### 433 COMPETING INTERESTS

R.E. reports being a board member of the Research Foundation on Wine and Nutrition, the
Beer and Health Foundation, and the European Foundation for Alcohol Research; personal
fees from KAO Corporation; lecture fees from Instituto Cervantes, Fundación Dieta
Mediterranea, Cerveceros de España, Lilly Laboratories, AstraZeneca, and Sanofi; and grants
from Novartis, Amgen, Bicentury, and Grand Fountaine. E.R. reports personal fees, grants,

and nonfinancial support from the California Walnut Commission and Alexion; and nonfinancial
support from the International Nut Council. J.S.-S. reports being a board member and personal
fees from Instituto Danone Spain; being a board member and grants from the International Nut
and Dried Fruit Foundation. The rest of the authors have nothing to disclose.

443

# 444 FUNDING

This work was supported by the Blanquerna School of Health Sciences (University Ramon Llull, Barcelona, Spain) and the Instituto de Salud Carlos III [grant number CD17/00122]. The funders had no role in the study design; the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. The views and opinions expressed in this paper are those of the authors only and do not necessarily reflect those of the funders.

451

#### 452 AUTHORS' CONTRIBUTIONS

453 M.H.H. was responsible for formal analyses, data interpretation, visualization, and drafting the 454 article. E.F. contributed to data interpretation and revised the article critically. C.L. contributed 455 to data interpretation and revised the article critically. O.C. contributed to data interpretation 456 and revised the article critically. R.E. contributed to funding and resource acquisition, 457 investigation, project administration, data interpretation, and revised the article critically. E.R. 458 contributed to funding and resource acquisition, investigation, project administration, data 459 interpretation, and revised the article critically. M.A.M.-G. contributed to funding and resource 460 acquisition, investigation, project administration, data interpretation, and revised the article 461 critically. D.C. contributed to funding and resource acquisition, investigation, project 462 administration, data interpretation, and revised the article critically. N.B. contributed to data 463 interpretation and revised the article critically. J.L. contributed to data interpretation and revised 464 the article critically. E.G.-G. contributed to data interpretation and revised the article critically. 465 F.A. contributed to data interpretation and revised the article critically. M.Fiol contributed to 466 data interpretation and revised the article critically. L.S.-M. contributed to data interpretation

467 and revised the article critically. A.R.M contributed to data interpretation and revised the article 468 critically. A.G. contributed to data interpretation and revised the article critically. C.O.-A. 469 contributed to data interpretation and revised the article critically. A.D.-L. contributed to data 470 interpretation and revised the article critically. M.Fitó contributed to funding and resource 471 acquisition, investigation, project administration, data interpretation, and revised the article 472 critically. A.H. coordinated the project, conceived and designed the study, contributed to 473 funding acquisition, was responsible for data curation, contributed to data interpretation, and 474 critically revised the article. M.H.H. and A.H. are the guarantors of this study, accept full 475 responsibility for the work and the conduct of the study, have access to the data, and controlled 476 the decision to publish. All authors read and approved the final manuscript.

477

# 478 ACKNOWLEDGEMENTS

We are extremely grateful to the PREDIMED Study participants for their collaboration. A full list of the names of all the PREDIMED Study collaborators is available in the **Appendix**. CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), CIBER de Epidemiología y Salud Pública (CIBERESP) and CIBER de Enfermedades Cardiovasculares (CIBERCV) are initiatives of Instituto de Salud Carlos III (Madrid, Spain), and are financed by the European Regional Development Fund.

#### 485 **REFERENCES**

486

487 1. GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12
488 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the
489 Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9:137–50.

2. Rehm J, Shield KD. Global Burden of Disease and the Impact of Mental and Addictive
Disorders. Curr Psychiatry Rep. 2019;21:10.

492 3. Charlson FJ, Baxter AJ, Dua T, Degenhardt L, Whiteford HA, Vos T. Excess mortality from
493 mental, neurological and substance use disorders in the Global Burden of Disease Study 2010.

494 Epidemiol Psychiatr Sci. 2015;24:121–40.

495 4. Patel V, Saxena S, Lund C, Thornicroft G, Baingana F, Bolton P, et al. The Lancet 496 Commission on global mental health and sustainable development. The Lancet. 497 2018;392:1553–98.

5. Maestre-Miquel C, López-de-Andrés A, Ji Z, de Miguel-Diez J, Brocate A, Sanz-Rojo S, et
al. Gender Differences in the Prevalence of Mental Health, Psychological Distress and
Psychotropic Medication Consumption in Spain: A Nationwide Population-Based Study. Int J
Environ Res Public Health. 2021;18:6350.

6. Carrasco-Garrido P, López de Andrés A, Hernández Barrera V, Jiménez-Trujillo I, JiménezGarcía R. National trends (2003-2009) and factors related to psychotropic medication use in
community-dwelling elderly population. Int Psychogeriatr. 2013;25:328–38.

7. Van Zoonen K, Buntrock C, Ebert DD, Smit F, Reynolds CF, Beekman AT, et al. Preventing
the onset of major depressive disorder: A meta-analytic review of psychological interventions.
Int J Epidemiol. 2014;43:318–29.

8. Carbon M, Correll CU. Clinical predictors of therapeutic response to antipsychotics in
schizophrenia. Dialogues Clin Neurosci. 2014;16:505–24.

510 9. Yu Z, Jiang H, Shao L, Zhou Y, Shi H, Ruan B. Use of antipsychotics and risk of myocardial

511 infarction: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82:624–32.

512 10. Loggia G, Attoh-Mensah E, Pothier K, Morello R, Lescure P, Bocca M-L, et al. Psychotropic

513 Polypharmacy in Adults 55 Years or Older: A Risk for Impaired Global Cognition, Executive

514 Function, and Mobility. Front Pharmacol. 2020;10:1659.

515 11. Bastos AA, Nogueira LR, Neto JV, Fisberg RM, Yannakoulia M, Ribeiro SML. Association
516 between the adherence to the Mediterranean dietary pattern and common mental disorders
517 among community-dwelling elders: 2015 Health Survey of São Paulo, SP, Brazil. J Affect
518 Disord. 2020;265:389–94.

519 12. Mortazavi SS, Mohammad K, Ardebili HE, Beni RD, Mahmoodi M, Keshteli AH. Mental
520 disorder prevention and physical activity in Iranian elderly. Int J Prev Med. 2012;3:S64-72.

521 13. Firth J, Solmi M, Wootton RE, Vancampfort D, Schuch FB, Hoare E, et al. A meta-review
522 of "lifestyle psychiatry": the role of exercise, smoking, diet and sleep in the prevention and
523 treatment of mental disorders. World Psychiatry Off J World Psychiatr Assoc WPA.
524 2020;19:360–80.

14. Lassale C, Batty GD, Baghdadli A, Jacka F, Sánchez-Villegas A, Kivimäki M, et al. Healthy
dietary indices and risk of depressive outcomes: a systematic review and meta-analysis of
observational studies. Mol Psychiatry. 2019;24:965–86.

528 15. Dinu M, Pagliai G, Casini A, Sofi F. Mediterranean diet and multiple health outcomes: an
529 umbrella review of meta-analyses of observational studies and randomised trials. Eur J Clin
530 Nutr. 2018;72:30–43.

531 16. Pattyn N, Cornelissen VA, Eshghi SRT, Vanhees L. The Effect of Exercise on the
532 Cardiovascular Risk Factors Constituting the Metabolic Syndrome: A Meta-Analysis of
533 Controlled Trials. Sports Med. 2013;43:121–33.

534 17. Clark JS, Simpson BS, Murphy KJ. The role of a Mediterranean diet and physical activity
535 in decreasing age-related inflammation through modulation of the gut microbiota composition.
536 Br J Nutr. 2022;128:1299–314.

537 18. Marx W, Moseley G, Berk M, Jacka F. Nutritional psychiatry: the present state of the 538 evidence. Proc Nutr Soc. 2017;76:427–36.

539 19. Bauer ME, Teixeira AL. Inflammation in psychiatric disorders: what comes first? Ann N Y
540 Acad Sci. 2019;1437:57–67.

541 20. Beurel E, Toups M, Nemeroff CB. The Bidirectional Relationship of Depression and
542 Inflammation: Double Trouble. Neuron. 2020;107:234–56.

543 21. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to
544 sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci.
545 2008;9:46–56.

546 22. Estruch R, Ros E, Salas-Salvadó J, Covas M-I, Corella D, Arós F, et al. Primary Prevention
547 of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil
548 or Nuts. N Engl J Med. 2018;378:e34.

549 23. Schröder H, Fitó M, Estruch R, Martínez-González MA, Corella D, Salas-Salvadó J, et al.

550 A Short Screener Is Valid for Assessing Mediterranean Diet Adherence among Older Spanish

551 Men and Women. J Nutr. 2011;141:1140–5.

552 24. Elosua R, Marrugat J, Molina L, Pons S, Pujol E. Validation of the Minnesota Leisure Time
553 Physical Activity Questionnaire in Spanish Men. Am J Epidemiol. 1994;139:1197–209.

Elosua R, Garcia M, Aguilar A, Molina L, Covas M-I, Marrugat J. Validation of the
Minnesota Leisure Time Physical Activity Questionnaire in Spanish Women: Med Sci Sports
Exerc. 2000;32:1431–7.

26. Ribó-Coll M, Castro-Barquero S, Lassale C, Sacanella E, Ros E, Toledo E, et al.
Mediterranean Diet and Physical Activity Decrease the Initiation of Cardiovascular Drug Use
in High Cardiovascular Risk Individuals: A Cohort Study. Antioxidants. 2021;10:397.

560 27. Martinez-Gonzalez MA, Corella D, Salas-Salvado J, Ros E, Covas MI, Fiol M, et al. Cohort
561 Profile: Design and methods of the PREDIMED study. Int J Epidemiol. 2012;41:377–85.

28. Castro-Barquero S, Ribó-Coll M, Lassale C, Tresserra-Rimbau A, Castañer O, Pintó X, et
al. Mediterranean Diet Decreases the Initiation of Use of Vitamin K Epoxide Reductase
Inhibitors and Their Associated Cardiovascular Risk: A Randomized Controlled Trial. Nutrients.
2020;12:3895.

29. Ribó-Coll M, Lassale C, Sacanella E, Ros E, Toledo E, Sorlí JV, et al. Mediterranean diet
and antihypertensive drug use: a randomized controlled trial. J Hypertens. 2021;39:1230–7.

30. Schmidt CO, Ittermann T, Schulz A, Grabe HJ, Baumeister SE. Linear, nonlinear or
categorical: how to treat complex associations? Splines and nonparametric approaches. Int J
Public Health. 2013;58:161–5.

31. Martínez-González MA, Montero P, Ruiz-Canela M, Toledo E, Estruch R, Gómez-Gracia
E, et al. Yearly attained adherence to Mediterranean diet and incidence of diabetes in a large
randomized trial. Cardiovasc Diabetol. 2023;22:262.

574 32. Gómez-Pinilla F. Brain foods: the effects of nutrients on brain function. Nat Rev Neurosci.
575 2008;9:568–78.

33. Bloch MH, Hannestad J. Omega-3 fatty acids for the treatment of depression: systematic
review and meta-analysis. Mol Psychiatry. 2012;17:1272–82.

34. Tryfonos C, Pavlidou E, Vorvolakos T, Alexatou O, Vadikolias K, Mentzelou M, et al.
Association of Higher Mediterranean Diet Adherence With Lower Prevalence of Disability and
Symptom Severity, Depression, Anxiety, Stress, Sleep Quality, Cognitive Impairment, and
Physical Inactivity in Older Adults With Multiple Sclerosis. J Geriatr Psychiatry Neurol.
2024;37:318–31.

- 35. Allcock L, Mantzioris E, Villani A. Adherence to a Mediterranean Diet Is Inversely
  Associated with Anxiety and Stress but Not Depression: A Cross-Sectional Analysis of
  Community-Dwelling Older Australians. Nutrients. 2024;16:366.
- 36. Costa R, Teasdale S, Abreu S, Bastos T, Probst M, Rosenbaum S, et al. Dietary Intake,
  Adherence to Mediterranean Diet and Lifestyle-Related Factors in People with Schizophrenia.
  Issues Ment Health Nurs. 2019;40:851–60.
- 589 37. Noetel M, Sanders T, Gallardo-Gómez D, Taylor P, Del Pozo Cruz B, van den Hoek D, et 590 al. Effect of exercise for depression: systematic review and network meta-analysis of 591 randomised controlled trials. BMJ. 2024;384:e075847.
- 38. Gordon BR, McDowell CP, Lyons M, Herring MP. The Effects of Resistance Exercise
  Training on Anxiety: A Meta-Analysis and Meta-Regression Analysis of Randomized
  Controlled Trials. Sports Med Auckl NZ. 2017;47:2521–32.
- 39. Duñabeitia I, Bidaurrazaga-Letona I, Diz JC, Colon-Leira S, García-Fresneda A, Ayán C.
  Effects of physical exercise in people with epilepsy: A systematic review and meta-analysis.
  Epilepsy Behav EB. 2022;137:108959.
- 40. Rißmayer M, Kambeitz J, Javelle F, Lichtenstein TK. Systematic Review and Meta-analysis
  of Exercise Interventions for Psychotic Disorders: The Impact of Exercise Intensity,
  Mindfulness Components, and Other Moderators on Symptoms, Functioning, and
  Cardiometabolic Health. Schizophr Bull. 2024;50:615–30.

- 41. Hershey MS, Martínez-González MÁ, Álvarez-Álvarez I, Martínez Hernández JA, RuizCanela M. The Mediterranean diet and physical activity: better together than apart for the
  prevention of premature mortality. Br J Nutr. 2022;128:1413–24.
- 42. Vuori I. Health benefits of physical activity with special reference to interaction with diet.
  Public Health Nutr. 2001;4:517–28.
- 607 43. Fox KR. The influence of physical activity on mental well-being. Public Health Nutr.608 1999;2:411–8.
- 44. Jacka FN, Berk M. Depression, diet and exercise. Med J Aust [Internet]. 2013 [cited 2024]
- 610 Oct 4];199. Available from: https://onlinelibrary.wiley.com/doi/abs/10.5694/mja12.10508
- 45. Fernández-Abascal B, Suárez-Pinilla P, Cobo-Corrales C, Crespo-Facorro B, Suárez-Pinilla M. In- and outpatient lifestyle interventions on diet and exercise and their effect on physical and psychological health: a systematic review and meta-analysis of randomised controlled trials in patients with schizophrenia spectrum disorders and first episode of psychosis. Neurosci Biobehav Rev. 2021;125:535–68.

# 617 SUPPLEMENTAL MATERIALS

618

Detailed list of antidepressants, anxiolytics, antipsychotics, and antiseizure drugs assessed in
the study

621 Antidepressants: agomelatine (Anatomical Therapeutic Chemical code: N06AX22), 622 amitriptyline (N06AA09), bupropion (N06AX12), citalopram (N06AB04), clomipramine 623 (N06AA04), desipramine (N06AA01), desvenlafaxine (N06AX23), doxepin (N06AA12), 624 dosulepin (N06AA16), duloxetine (N06AX21), escitalopram (N06AB10), fluoxetine (N06AB03), 625 imipramin (N06AA02), maprotiline (N06AA21), mianserin (N06AX03), mirtazapine (N06AX11), 626 moclobemide (N06AG02), nortriptyline (N06AA10), oxitriptan (N06AX01), paroxetine 627 (N06AB05), reboxetine (N06AX18), sertraline (N06AB06), trazodone (N06AX05), and 628 venlafaxine (N06AX16).

<u>Anxiolytics</u>: alprazolam (N05BA12), bentazepam (N05BA24), bromazepam (N05BA08),
brotizolam (N05CD09), buspirone (N05BE01), clobazam (N05BA09), clonazepam (N03AE01),
clordiazepoxide (N05BA02), clorazepate (N05BA05), diazepam (N05BA01), flunitrazepam
(N05CD03), flurazepam (N05CD01), halazepam (N05BA13), ketazolam (N05BA10),
lorazepam (N05BA06), lormetazepam (N05CD06), loprazolam (N05CD11), medazepam
(N05BA03), midazolam (N05CD08), pinazepam (N05BA14), tepazepam (N05BA01), triazolam
(N05CD05), zaleplon (N05CF03), zolpidem (N05CF02), and zopiclone (N05CF01).

<u>Antipsychotics</u>: amisulpride (N05AL05), chlorpromazine (N05AA01), clotiapine (N05AH06),
flupentixol (N05AF01), fluphenazine (N05AB02), haloperidol (N05AD01), levomepromazine
(N05AA02), olanzapine (N05AH03), perphenazine (N05AB03), pimozide (N05AG02),
quetiapine (N05AH04), risperidone (N05AX08), sulpiride (N05AL01), thioridazine (N05AC02),
tiapride (N05AL03), and ziprasidone (N05AE04).

<u>Antiseizure drugs</u>: carbamazepine (N03AF01), clonazepam (N03AE01), gabapentin
(N02BF01), lamotrigine (N03AX09), levetiracetam (N03AX14), oxcarbazepine (N03AF02),
phenobarbital (N03AA02), phenytoin (N03AB02), pregabalin (N02BF02), primidone

- 644 (N03AA03), tiagabine (N03AG06), topiramate (N03AX11), valproic acid (N03AG01),
- 645 valpromide (N03AG02), and zonisamide (N03AX15).

#### 646 **APPENDIX**

647

# 648 Full list of PREDIMED study collaborators

- 649 Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain: R.
- 650 Estruch, M. Serra, A. Pérez-Heras, C. Viñas, R. Casas, L. de Santamaría, S. Romero, E.
- 651 Sacanella, G. Chiva, P. Valderas, S. Arranz, J.M. Baena, M. García, M. Oller, J. Amat, I.
- 652 Duaso, Y. García, C. Iglesias, C. Simón, L. Quinzavos, L. Parra, M. Liroz, J. Benavent, J. Clos,
- 653 I. Pla, M. Amorós, M.T. Bonet, M.T. Martin, M.S. Sánchez, J. Altirriba, E. Manzano, A. Altés,
- M. Cofán, C. Valls-Pedret, A. Sala-Vila, M. Doménech, R. Gilabert, and N. Bargalló.
- 655 University of Navarra, Primary Care Centres, Pamplona, Spain: M.Á. Martínez-González, A.
- 656 Sánchez-Tainta, B. Sanjulián, E. Toledo, M. Bes-Rastrollo, A. Martí, C. Razquin, P. Buil-
- 657 Cosiales, M. Serrano-Martínez, J. Díez-Espino, A. García-Arellano, I. Zazpe, F.J. Basterra-

658 Gortari, E.H. Martínez-Lapiscina, A. Gea, M. Garcia-Lopez, J.M. Nuñez-Córdoba, N. Ortuño,

- N. Berrade, V. Extremera-Urabayen, C. Arroyo-Azpa, L García-Pérez, J. Villanueva-Tellería,
- 660 F. Cortés-Ugalde, T. Sagredo-Arce, M<sup>a</sup> D. García de la Noceda-Montoy, M<sup>a</sup> D. Vigata-López,
- 661 M<sup>a</sup> T. Arceiz-Campo, A. Urtasun-Samper, M<sup>a</sup> V. Gueto-Rubio, and B. Churio-Beraza.
- University of Valencia, Valencia, Spain; Universitat Jaume I, Castellon, Spain; and Conselleria
  de Sanitat, Generalitat Valenciana: D. Corella, P. Carrasco, C. Ortega-Azorín, E.M. Asensio,
  R. Osma, R. Barragán, F. Francés, M. Guillén, J.I. González, C. Sáiz, O. Portolés, F.J.
  Giménez, O. Coltell (U. Jaume I), R. Fernández-Carrión, I. González-Monje, L. Quiles, V.
  Pascual, C. Riera, M.A. Pages, D. Godoy, A. Carratalá-Calvo, S. Sánchez-Navarro, and C.
- 667 Valero-Barceló.
- University Rovira i Virgili, Reus, Spain: J. Salas-Salvadó, M. Bulló, R. González, C. Molina, F.
  Márquez, N. Babio, M. Sorlí, J. García-Roselló, F. Martin, R. Tort, A. Isach, B. Costa, J.J.
  Cabré, J. Fernández-Ballart, N. Ibarrola, C. Alegret, P. Martínez, S. Millán, J.L. Piñol, J.
  Basora, and J.M. Hernández.

- 672 Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain: M. Fitó, M.I. Covas, O.
- 673 Castañer, S. Tello, J. Vila, H. Schröder, R. De la Torre, D. Muñoz-Aguayo, N. Molina, E.
- 674 Maestre, A. Rovira, R. Elosua, and M. Farré.
- 675 University Hospital of Alava, Vitoria, Spain: F. Arós, I. Salaverría, T. del Hierro, J. Algorta, S.
- 676 Francisco, A. Alonso-Gómez, J. San-Vicente, E. Sanz, I. Felipe, A. Alonso-Gómez, and A.
- 677 Loma-Osorio.
- University of Málaga, Málaga, Spain: E. Gómez-Gracia, R. Benítez-Pont, M. Bianchi-Alba, J.
- 679 Fernández-Crehuet Navajas, J. Wärnberg, R. Gómez-Huelgas, J. Martínez-González, V.
- 680 Velasco-García, J. de Diego-Salas, A. Baca-Osorio, J. Gil-Zarzosa, J.J. Sánchez-Luque, and
- 681 E. Vargas-López.
- 682 Institute of Health Sciences, University of Balearic Islands, and Hospital Son Espases, Palma
- 683 de Mallorca, Spain: M. Fiol, M. García-Valdueza, M. Moñino, A. Proenza, R. Prieto, G.
- 684 Frontera, M. Ginard, F. Fiol, A. Jover, and J. García.
- 685 Department of Family Medicine, Primary Care Division of Sevilla, Sevilla, Spain: J. Lapetra, M.
- Leal, E. Martínez, J.M. Santos, M. Ortega-Calvo, P. Román, F.J. García, P. Iglesias, Y.
- 687 Corchado, E. Mayoral, and C. Lama.
- 688 University of Las Palmas de Gran Canaria, Las Palmas, Spain: L. Serra-Majem, J. Álvarez-
- 689 Pérez, E. Díez-Benítez, I. Bautista-Castaño, I. Maldonado-Díaz, A. Sánchez-Villegas, F.
- 690 Sarmiendo-de la Fe, C. Simón-García, I. Falcón-Sanabria, B. Macías-Gutiérrez, and A.J.
- 691 Santana-Santana.
- Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain: X. Pintó, E. de
  la Cruz, A. Galera, Y. Soler, F. Trias, I. Sarasa, E. Padres, R. Figueras, X. Solanich, R. Pujol
  and E. Corbella.
- 695 Clinical End Point Committee: F. Arós (chair), M. Aldamiz, A. Alonso-Gómez, J. Berjón, L.
  696 Forga, J. Gállego, M. A. García-Layana, A. Larrauri, J. Portu, J. Timiraus, and M. Serrano697 Martínez.